🏛️ Verified NIH Record • Updated 2026-07-17
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (NCT04685135)
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Mirati Therapeutics Inc.
🩺 Plain-English Summary (8th-Grade Level)
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 012-898 — Cerritos, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (380 Sites)
Showing the first 25 of 380 sites.
- Local Institution - 012-898 — Cerritos, California
- Local Institution - 012-910 — Duarte, California
- Local Institution - 012-898 D — Glendale, California
- Local Institution - 012-910-A — Huntington Beach, California
- Local Institution - 012-910-C — Irvine, California
- Local Institution - 012-910-B — Long Beach, California
- Local Institution - 012-910-F — Long Beach, California
- Local Institution - 012-910-D — Newport Beach, California
- Local Institution - 012-898 C — Santa Ana, California
- Local Institution - 012-858 — Santa Rosa, California
- Local Institution - 012-910-E — Torrance, California
- Local Institution - 012-951-B — Denver, Colorado
- Local Institution - 012-951 — Lafayette, Colorado
- Local Institution - 012-872 — Lone Tree, Colorado
- Local Institution - 012-951-A — Wheat Ridge, Colorado
- Local Institution - 012-562-B — Fleming Island, Florida
- Local Institution - 012-968 — Fort Lauderdale, Florida
- Local Institution - 012-562-D — Jacksonville, Florida
- Local Institution - 012-853 — Jacksonville, Florida
- Local Institution - 012-562-E — Jacksonville, Florida
- Local Institution - 012-562-A — Jacksonville, Florida
- Local Institution - 012-562-C — Jacksonville, Florida
- Local Institution - 012-562-F — Jacksonville, Florida
- Local Institution - 012-562-G — Jacksonville, Florida
- Local Institution - 012-562 — Jacksonville, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Non Small Cell Lung Cancer
- Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Chandler, Arizona
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) — St Louis, Missouri
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Daphne, Alabama
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — Gilbert, Arizona
- MOv19-BBz CAR T Cells in FRa+ Cancers — Philadelphia, Pennsylvania
Explore by condition: All Metastatic Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.